{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:14:49Z","timestamp":1789906489107,"version":"4.0.1"},"reference-count":211,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.survophthal.2023.01.002","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T17:50:54Z","timestamp":1674150654000},"page":"103-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Update on the systemic management of noninfectious uveitis in children and adolescents"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9622-8779","authenticated-orcid":false,"given":"In\u00eas","family":"Leal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura R.","family":"Steeples","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiao Wei","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Giuffr\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasa","family":"Pockar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elspeth K.Y.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Sieu Eng","family":"Chieng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Ashworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.survophthal.2023.01.002_bib0001","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.semarthrit.2018.11.004","article-title":"Update of the evidence-based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis","volume":"49","author":"Heiligenhaus","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0002","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00467-015-3216-1","article-title":"Behavioural abnormalities in children with new-onset nephrotic syndrome receiving corticosteroid therapy: results of a prospective longitudinal study","volume":"31","author":"Upadhyay","year":"2016","journal-title":"Paediatr Nephrol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0003","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jpeds.2015.07.048","article-title":"Identifying differences in risk factors for depression and anxiety in pediatric chronic disease: a matched cross-sectional study of youth with lupus\/mixed connective tissue disease and their peers with diabetes","volume":"167","author":"Knight","year":"2015","journal-title":"J Pediatr"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0004","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-020-04796-z","article-title":"Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST-adalimumab in juvenile idiopathic arthritis-associated uveitis stopping trial): study protocol for a randomised controlled trial","volume":"21","author":"Acharya","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0005","unstructured":"Adalimumab use in paediatric and adolescent rheumatology, Information for health proffesionals. Br Soc Rheumatgol Paediatr Adolesc Guid https:\/\/www.rheumatology.org.uk\/Portals\/0\/Documents\/Guidelines\/PaediatricguidelinesAdalimumab_Paediatric_Rheumatology.pdf?ver=2020-03-19-150326-343."},{"key":"10.1016\/j.survophthal.2023.01.002_bib0006","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1093\/rheumatology\/keac140","article-title":"Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseases under immunomodulatory treatment: a preliminary study","volume":"61","author":"Akg\u00fcn","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0007","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.vaccine.2022.01.061","article-title":"Exploring the attitudes, concerns, and knowledge regarding COVID-19 vaccine by the parents of children with rheumatic disease: cross-sectional online survey","volume":"40","author":"Akg\u00fcn","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0008","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/bjophthalmol-2018-313789","article-title":"Areas of agreement in the management of childhood non-infectious chronic anterior uveitis in the UK","volume":"104","author":"Solebo","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0009","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/archdischild-2015-309522","article-title":"Systematic review of the toxicity of short-course oral corticosteroids in children archives of disease in childhood","volume":"101","author":"Aljebab","year":"2016","journal-title":"Archives of Disease in Childhood"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0010","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/acr.23610","article-title":"Childhood arthritis and rheumatology research alliance consensus treatment plans for juvenile idiopathic arthritis-associated and idiopathic chronic anterior uveitis","volume":"71","author":"ST","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0011","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/art.40885","article-title":"American College of Rheumatology\/Arthritis Foundation Guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis","volume":"71","author":"ST","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0012","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/acr.23871","article-title":"American College of Rheumatology\/Arthritis Foundation Guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis\u2013associated uveitis","volume":"71","author":"ST","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0013","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/acr.22627","article-title":"Using the effects of youngsters\u2019 eyesight on quality of life questionnaire to measure visual outcomes in children with uveitis","volume":"67","author":"ST","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0014","first-page":"216","article-title":"Biosimilars in pediatric rheumatology and their introduction into routine care","author":"Aragon Cuevas","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2007.08.018","article-title":"Infliximab to treat chronic non-infectious uveitis in children: retrospective case series with long-term follow-up","volume":"144","author":"Ardoin","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0016","first-page":"1","article-title":"Safety of COVID-19 vaccines and disease flares after vaccines in children with rheumatic disease","author":"Arslanoglu Aydin","year":"2022","journal-title":"Postgrad Med"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0017","doi-asserted-by":"crossref","unstructured":"Ashkenazy N, Saboo US, Abraham A, Ronconi C, Cao JH. Successful treatment with infliximab after adalimumab failure in pediatric non-infectious uveitis. J AAPOS. 2019; 151(e1-151.e5). doi:10.1016\/j.jaapos.2019.02.006.","DOI":"10.1016\/j.jaapos.2019.02.006"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta23150","article-title":"Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT","volume":"23","author":"Ramanan","year":"2019","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0019","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0020","first-page":"e135","article-title":"Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial, Lancet Rheumatol","author":"Ramanan","year":"2020","journal-title":"2"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0021","doi-asserted-by":"crossref","unstructured":"Babu K, Sudheer B, Rao AP Intravenous tocilizumab in idiopathic pediatric uveitis with refractory cystoid macular edema - a case report. Indian J Ophthalmol 2019;67:975-977.","DOI":"10.4103\/ijo.IJO_1938_18"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0022","doi-asserted-by":"crossref","unstructured":"Becker I, Horneff G. Risk of serious infection in juvenile idiopathic arthritis patients associated with tumor necrosis factor inhibitors and disease activity in the German biologics in Pediatric Rheumatology Registry.2017","DOI":"10.1002\/acr.22961"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0023","article-title":"CARRA Registry investigators. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry","author":"Beukelman","year":"201239","journal-title":"J Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0024","article-title":"Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment","author":"Beukelman","year":"201264","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0025","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2006.103721","article-title":"Adalimumab in the therapy of uveitis in childhood","volume":"91","author":"Biester","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0026","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.3899\/jrheum.151389","article-title":"Comparable efficacy of abatacept used as first-line or second-line biological agent for severe juvenile idiopathic arthritis-related uveitis","volume":"43","author":"Birolo","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0027","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00296-015-3231-3","article-title":"Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus","volume":"35","author":"Bou","year":"2015","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0028","unstructured":"British Society for rheumatology paediatric and adolescent guidance notes, 2022, Br Soc Rheumatgoloy, https:\/\/www.rheumatology.org.uk\/practice-quality\/guidelines\/paediatric-adolescent-guidance Published online."},{"key":"10.1016\/j.survophthal.2023.01.002_bib0029","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1007\/s00296-012-2642-7","article-title":"Clinical trial of etanercept tapering in juvenile idiopathic arthritis during remission","volume":"33","author":"Cai","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0030","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/art.39940","article-title":"Anti\u2013interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis\u2013associated uveitis refractory to anti\u2013tumor necrosis factor therapy: a multicenter study of twenty-five patients","volume":"69","author":"Calvo-R\u00edo","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12969-018-0266-5","article-title":"Outcomes of non-infectious paediatric uveitis in the era of biologic therapy","volume":"16","author":"Cann","year":"2018","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/13543784.2012.636350","article-title":"Treatment strategies for childhood noninfectious chronic uveitis: an update","volume":"21","author":"Cantarini","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0033","article-title":"Mycophenolate mofetil monotherapy in the management of paediatric uveitis","author":"Chang","year":"201125","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0034","article-title":"The COVID-19 vaccine: attitudes and vaccination in patients with autoimmune inflammatory rheumatic diseases","volume":"15","author":"Chen","year":"2022","journal-title":"Rheumatol Autoimmun"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0035","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2174\/1566524015666150731100012","article-title":"Cytokine expression profile in aqueous humor and sera of patients with acute anterior uveitis","volume":"15","author":"Chen","year":"2015","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0036","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jns.2006.01.012","article-title":"Adalimumab-associated optic neuritis","volume":"244","author":"Chung","year":"2006","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0037","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10067-017-3890-4","article-title":"Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis","volume":"37","author":"Correll","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0038","series-title":"Clinical Commissioning Policy Statement: Biologic Therapies for the treatment of Juvenile Idiopathic Arthritis (JIA). Reference: NHS England E03X04. author: Specialised Commissioning Team, NHS England","year":"2015"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0039","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/annrheumdis-2018-213131","article-title":"Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative","volume":"77","author":"Constantin","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0040","first-page":"37","article-title":"Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis","author":"Correll","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0041","doi-asserted-by":"crossref","unstructured":"Davies R, D DC, Kearsley-Fleet L, et\u00a0al. The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data. Rheumatol 59(PG-1391-1397):1391-1397. doi:10.1093\/rheumatology\/kez449.","DOI":"10.1093\/rheumatology\/kez449"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0042","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1002\/art.39197","article-title":"Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept: results from the british society for paediatric and adolescent rheumatology etanercept Cohort Study","volume":"67","author":"Davies","year":"2015","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0043","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ajo.2020.08.005","article-title":"Recurrence rates of inflammation after switching from the originator infliximab to biosimilar infliximab-abda for noninfectious uveitis","volume":"225","author":"Deaner","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0044","first-page":"658","article-title":"Adenotonsillectomy as a treatment option for poststreptococcal uveitis","volume":"112","author":"Ovchinsky","year":"2002"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0045","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","article-title":"Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (FOCUS) initiative","volume":"125","author":"Dick","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0046","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0047","doi-asserted-by":"crossref","first-page":"xvi","DOI":"10.1016\/j.ajo.2018.03.028","article-title":"Chronic anterior uveitis in children: psychosocial challenges for patients and their families","volume":"191","author":"Parker","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0048","doi-asserted-by":"crossref","unstructured":"Doran MF, Crowson CS, Pond GR. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46:2287\u201393.","DOI":"10.1002\/art.10524"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0049","doi-asserted-by":"crossref","unstructured":"Doycheva D, Deuter C, Stuebiger N, Biester S, Zierhut M. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 91:180\u2013184.","DOI":"10.1136\/bjo.2006.094698"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0050","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/bjophthalmol-2015-306701","article-title":"Mycophenolate sodium for the treatment of chronic non-infectious uveitis of childhood","volume":"100","author":"Doycheva","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0051","doi-asserted-by":"crossref","first-page":"907","DOI":"10.55563\/clinexprheumatol\/r4gnxm","article-title":"Drug survival of the infliximab biosimilar (CT-P13) in paediatric patients with non-infectious uveitis","volume":"39","author":"S\u00f6zeri","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0052","first-page":"253","article-title":"Position paper on tuberculosis screening in patients with immune mediated inflammatory diseases candidates for biological therapy","volume":"37","author":"Duarte","year":"2012","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0053","first-page":"S164","article-title":"Budd-Chiari syndrome revealing a very vascular juvenile Behcet's disease","volume":"36","author":"Echchilali","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0054","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clim.2011.01.014","article-title":"Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis","volume":"139","author":"El-Asrar","year":"2011","journal-title":"Clin Immunol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0055","first-page":"63","article-title":"Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et\u00a0al","author":"Elhai","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0056","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2147\/OPTH.S83950","article-title":"Causes of uveitis in children without juvenile idiopathic arthritis","volume":"9","author":"Engelhard","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0057","doi-asserted-by":"crossref","unstructured":"ES S, AD D, AV R. Uveitis associated with juvenile idiopathic arthritis. Nat Rev Rheumatol. 2015; 11(PG-338-48):338-348. doi:10.1038\/nrrheum.2015.20.","DOI":"10.1038\/nrrheum.2015.20"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0058","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01468","article-title":"The role of biosimilars in uveitis: long-term real-world outcomes of the switch from original to biosimilar TNF-alpha inhibitors","volume":"10","author":"Fabiani","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0059","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12969-018-0255-8","article-title":"Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting","volume":"16","author":"Ferrara","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0060","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12969-019-0345-2","article-title":"Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for uveitis in childhood","volume":"17","author":"Foeldvari","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0061","article-title":"New and updated recommendations for the treatment of juvenile idiopathic arthritis associated uveitis and idiopathic chronic anterior uveitis","author":"Foeldvari","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0062","first-page":"1146","article-title":"Tumor necrosis factor-\u03b1 blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey","volume":"34","author":"Foeldvari","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0063","first-page":"362","article-title":"Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis","volume":"32","author":"Foeldvari","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0064","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaapos.2005.04.005","article-title":"Clinical course and outcome of uveitis in children","volume":"9","author":"Friling","year":"2005","journal-title":"J AAPOS"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0065","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1089\/cap.2018.0017","article-title":"Steroid-induced psychosis in the pediatric population: a new case and review of the literature","volume":"28","author":"Hodgins","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0066","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2012-202220","article-title":"The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis","volume":"72","author":"Garc\u00eas","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0067","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550","volume":"186","author":"GhoreschI","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0068","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0069","doi-asserted-by":"crossref","unstructured":"Holland GN, Stiehm ER. Special considerations in the evaluation and management of uveitis in children. Am J Ophthalmol. 2003; 135(PG-867-78): 867-878. doi:10.1016\/s0002-9394(03)00314-3.","DOI":"10.1016\/S0002-9394(03)00314-3"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0070","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ccm.2019.07.003","article-title":"Tuberculosis and biologic therapies: anti-tumor necrosis factor-\u03b1 and beyond","volume":"40","author":"Godfrey","year":"2019","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0071","article-title":"Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis","author":"Goebel","year":"201195","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0072","first-page":"573","article-title":"Management of perioperative tumour necrosis factor \u03b1 inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis","volume":"55","author":"Goodman","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0073","doi-asserted-by":"crossref","unstructured":"Gordon DM, McLean JM. Effects of pituitary adrenocorticotrophic hormone (ACTH) therapy in ophthalmologic conditions. JAMA 142:1271\u20131276.","DOI":"10.1001\/jama.1950.02910340017005"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0074","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/cei.13112","article-title":"Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab","volume":"192","author":"Gorovits","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0075","series-title":"COVID-19: guidance for people whose immune system means they are at higher risk","year":"2022"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0076","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1089\/jop.2020.0081","article-title":"Anti-tumor necrosis factor treatment in the management of pediatric noninfectious uveitis: infliximab versus adalimumab","volume":"37","author":"Gunduz","year":"2021","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0077","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/17469899.2021.1935240","article-title":"Adalimumab in the treatment of pediatric patients with chronic noninfectious anterior uveitis","volume":"16","author":"Gunzinger","year":"2021","journal-title":"Expert Rev Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0078","doi-asserted-by":"crossref","unstructured":"H. R, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 335:1369\u20131377.","DOI":"10.1056\/NEJM199610313351807"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0079","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/1756-185X.14279","article-title":"Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: a single-center study","volume":"25","author":"Haslak","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0080","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.survophthal.2015.10.005","article-title":"Managing juvenile idiopathic arthritis-associated uveitis","volume":"61","author":"Hawkins","year":"2016","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0081","doi-asserted-by":"crossref","unstructured":"Heijstek MW, Bruin LM, Bijl M, et\u00a0al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis;70.","DOI":"10.1136\/ard.2011.150193"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0082","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.semarthrit.2018.11.004","article-title":"Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis","volume":"49","author":"Heiligenhaus","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0083","doi-asserted-by":"crossref","unstructured":"Heiligenhaus A, Mingels A, Heinz C, Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol 17:743\u20138.","DOI":"10.1177\/112067210701700509"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0084","doi-asserted-by":"crossref","unstructured":"Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab. Rheumatol (Oxford). 2011;50: doi:10.1093\/rheumatology\/ker107.","DOI":"10.1093\/rheumatology\/ker107"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0085","first-page":"32","article-title":"Immunosuppressive drugs in the management of progressive, corticosteroid-resistant uveitis associated with juvenile rheumatoid arthritis","author":"Hemady","year":"1992","journal-title":"Int Ophthalmol Clin. Winter."},{"key":"10.1016\/j.survophthal.2023.01.002_bib0086","unstructured":"Highlights of prescribing information SIMPONI. Accessed 2022, https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/SIMPONI-pi.pdf."},{"key":"10.1016\/j.survophthal.2023.01.002_bib0087","doi-asserted-by":"crossref","unstructured":"Holroyd CR, Seth R, Bukhari M, et\u00a0al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis-Executive summary. Rheumatol (Oxford) 1;58:22.","DOI":"10.1093\/rheumatology\/key207"},{"issue":"4","key":"10.1016\/j.survophthal.2023.01.002_bib0088","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.tjo.2015.03.004","article-title":"Immunosuppressive therapy for eye diseases: effectiveness, safety, side effects and their prevention","volume":"5","author":"Hornbeak","year":"2015","journal-title":"Taiwan J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0089","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jpeds.2018.05.042","article-title":"Safety of adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriasis, and Crohn\u2019s disease","volume":"201","author":"Horneff","year":"2018","journal-title":"J Pediatr"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0090","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ajo.2019.06.007","article-title":"Adalimumab in juvenile idiopathic arthritis-associated uveitis: 5-year follow-up of the Bristol participants of the SYCAMORE trial","volume":"207","author":"Horton","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0091","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1136\/annrheumdis-2016-210629","article-title":"Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate","volume":"76","author":"Humphreys","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0092","doi-asserted-by":"crossref","DOI":"10.1186\/1546-0096-10-31","article-title":"Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology","volume":"10","author":"Ilowite","year":"2012","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0093","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s10067-012-2082-5","article-title":"Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan","volume":"31","author":"Imagawa","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0094","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2017.08.007","article-title":"Immunosuppression for the uveitides","volume":"125","author":"Jabs","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0095","doi-asserted-by":"crossref","DOI":"10.1111\/j.1442-9071.2005.00938.x","article-title":"Clinical features and visual outcome of intermediate uveitis in children","volume":"33","author":"Jain","year":"2005","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0096","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","article-title":"The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases","volume":"53","author":"Jani","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0097","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/370151a0","article-title":"Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2","volume":"370","author":"Johnston","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0098","doi-asserted-by":"crossref","unstructured":"Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006; 4(e2). doi:10.1016\/j.ophtha.2006.01.005.","DOI":"10.1016\/j.ophtha.2006.01.005"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2006.05.002","article-title":"Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists","volume":"73","author":"Kamal","year":"2006","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0100","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00417-010-1523-6","article-title":"Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis","volume":"249","author":"Kenawy","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0101","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3109\/09273941003739910","article-title":"Treatment of pediatric Vogt-Koyanagi-Harada syndrome with infliximab","volume":"18","author":"Khalifa","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0102","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.090482","article-title":"Monitoring methotrexate toxicity in juvenile idiopathic arthritis","volume":"36","author":"Kocharla","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0103","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00296-020-04663-9","article-title":"Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19","volume":"40","author":"Koker","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0104","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ophtha.2013.07.019","article-title":"Infliximab for the treatment of refractory noninfectious uveitis: a study of 88 patients with long-term follow-up","volume":"121","author":"Kruh","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0105","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ajo.2020.10.013","article-title":"A Systematic switch from originator infliximab to biosimilar infliximab in patients with non-infectious uveitis","volume":"225","author":"Kumar","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0106","first-page":"2442","article-title":"Ykujiki HJm Haapasaari J. Hepatotoxicity and patient with juvenile idiopathic arthritis receiving longterm methotrexate therapy","volume":"29","author":"Lahdenne","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0107","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-021-00630-1","article-title":"Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to adalimumab","volume":"19","author":"Lanz","year":"2021","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0108","doi-asserted-by":"crossref","unstructured":"Lanz S, Skrabl-Baumgartner A, Andrea S. ORCID: http:\/\/orcid.org\/0000-0001-7797-3124 GAOSB. Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to adalimumab. Pediatr Rheumatol. 2021;19:132. doi:10.1186\/s12969-021-00630-1 .","DOI":"10.1186\/s12969-021-00630-1"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0109","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114003","article-title":"Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits","volume":"198","author":"Laserna-Mendieta","year":"2021","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0110","first-page":"49","article-title":"The 2021 Portuguese Society of Ophthalmology joint guidelines with paediatric rheumatology on the screening, monitoring and medical treatment of juvenile idiopathic arthritis-associated uveitis","volume":"1","author":"Leal","year":"2022","journal-title":"Acta Reum Port"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0111","first-page":"49","article-title":"The 2021 Portuguese Society of Ophthalmology joint guidelines with paediatric rheumatology on the screening, monitoring and medical treatment of juvenile idiopathic arthritis-associated uveitis","volume":"1","author":"Leal","year":"2022","journal-title":"ARP Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0112","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.3390\/jcm9113599","article-title":"Biotherapies in Uveitis","volume":"9","author":"Leclercq","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0113","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/rheumatology\/kex049","article-title":"Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis","volume":"57","author":"Lee","year":"2018","journal-title":"Rheumatology"},{"issue":"7\u20138","key":"10.1016\/j.survophthal.2023.01.002_bib0114","first-page":"1564","article-title":"Escalation to weekly adalimumab for the treatment of ocular inflammation","volume":"29","author":"Liberman","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0115","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-020-00422-z","article-title":"COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country","volume":"18","author":"Licciardi","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0116","article-title":"The safety and efficacy of noncorticosteroid triple immunosuppressive therapy in treating refractory chronic non-infectious uveitis in childhood","author":"Little","year":"201441","journal-title":"J Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0117","doi-asserted-by":"crossref","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0118","doi-asserted-by":"crossref","unstructured":"Lopez-Gonzalez R, Loza E, Jover JA, et\u00a0al. Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study. 2009;38:58-62. doi:10.1080\/03009740802366076.","DOI":"10.1080\/03009740802366076"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0119","doi-asserted-by":"crossref","unstructured":"Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ. Etanercept in children with polyarticular juvenile rheumatoid arthritis. New Engl J Med 342:763\u20139.","DOI":"10.1056\/NEJM200003163421103"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0120","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/377065a0","article-title":"Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID","volume":"377","author":"Macchi","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0121","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaa595","article-title":"Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis","author":"Maccora","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0122","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/rheumatology\/keab572","article-title":"OBSIDIAn - real world evidence of originator to BioSImilar drug switch in juvenile idiopathic arthritis","volume":"61","author":"Maccora","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0123","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/BOR.0000000000000723","article-title":"Update on noninfectious uveitis in children and its treatment","volume":"32","author":"Maccora","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0124","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/09273948.2020.1817501","article-title":"Tocilizumab employment in the treatment of resistant juvenile idiopathic arthritis associated uveitis","volume":"29","author":"Maleki","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"10.1016\/j.survophthal.2023.01.002_bib0125","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.survophthal.2021.06.006","article-title":"Pediatric uveitis: A comprehensive review","volume":"67","author":"Maleki","year":"2022","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0126","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bjo.2004.054239","article-title":"The use of low dose methotrexate in children with chronic anterior and intermediate uveitis","volume":"89","author":"Malik","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0127","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.682327","article-title":"Long term experience in patients with JIA-associated uveitis in a large referral center","volume":"9","author":"Marelli","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0128","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00417-015-3140-x","article-title":"Long-term efficacy of abatacept in pediatric patients with idiopathic uveitis: a case series","volume":"253","author":"Marrani","year":"2015","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0129","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00417-015-3140-x","article-title":"Long-term efficacy of abatacept in pediatric patients with idiopathic uveitis: a case series","volume":"253","author":"Marrani","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0130","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12969-019-0330-9","article-title":"Defining outcome measures in juvenile idiopathic arthritis associated uveitis by a systematic review analysis: do we need a consensus?","volume":"17","author":"Mastrangelo","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0131","first-page":"3194","article-title":"Anti-drug antibodies to monoclonal TNF inhibitors in non-infectious uveitis","volume":"63","author":"McHarg","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0132","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1080\/09273948.2021.1936565","article-title":"Anti-adalimumab antibodies in patients with non-infectious ocular inflammatory disease: a case series","volume":"30","author":"McKay","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0133","unstructured":"McLean LP, Cross RK. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.survophthal.2023.01.002_bib0134","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/cei.12295","article-title":"Interleukin-6 blockade in ocular inflammatory diseases","volume":"176","author":"Mesquida","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0135","unstructured":"Methotrexate use in paediatric and adolescent rheumatology, Information for health proffesionals. Br Soc Rheumatgoloy Paediatr Adolesc Guid. British Society for Rheumatology https:\/\/www.rheumatology.org.uk\/practice-quality\/guidelines\/paediatric-adolescent-guidance."},{"key":"10.1016\/j.survophthal.2023.01.002_bib0136","unstructured":"Methrotrexate guidelines for the use in children, NICE guidelines. https:\/\/bnfc.nice.org.uk\/drug\/methotrexate.html"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0137","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000336188","article-title":"Rituximab for noninfectious uveitis","volume":"51","author":"Miserocchi","year":"2012","journal-title":"Dev Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0138","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/bjophthalmol-2015-306790","article-title":"Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis","volume":"100","author":"Miserocchi","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0139","doi-asserted-by":"crossref","unstructured":"Miserocchi E, Pontikaki I, Modorati G, Gattinara M, PL M, Gerloni V. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev 11( PG-35-9):35-39. doi:10.1016\/j.autrev.2011.07.001.","DOI":"10.1016\/j.autrev.2011.07.001"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0140","article-title":"Population-based study of outcomes of patients with juvenile idiopathic arthritis (JIA) compared to non-JIA subjects","volume":"46","author":"ML","year":"2017","journal-title":"Semin arthritis Rheum"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0141","doi-asserted-by":"crossref","unstructured":"Mycophenolate mofetil therapy in the management of inflammatory bowel disease \u2013 a retrospective case series and review. J Crohn\u2019s Colitis, 8, 2014, 890\u2013897.","DOI":"10.1016\/j.crohns.2014.01.014"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0142","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Gallego A, Barral E, Enr\u00edquez E, Tejada P, Barcel\u00f3 A, J de I. Adalimumab for the treatment of refractory noninfectious paediatric uveitis. Int Ophthalmol. 2017; 37(PG-719-725):719-725. doi:10.1007\/s10792-016-0293-5.","DOI":"10.1007\/s10792-016-0293-5"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0143","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1517\/14740338.2016.1112375","article-title":"Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?","volume":"15","author":"Murdaca","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0144","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s40265-021-01610-1","article-title":"Biosimilar-to-biosimilar switching: what is the rationale and current experience?","volume":"81","author":"Mysler","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0145","series-title":"Adalimumab and dexamethasone for treating non-infectious uveitis, National Institute for Health and Care Excellence","year":"2021"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0146","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2165\/00148581-200608060-00003","article-title":"Recommendations for the use of methotrexate in juvenile idiopathic arthritis","volume":"8","author":"Niehues","year":"2003","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0147","unstructured":"Paediatric Formulary Committee. BNF for Children (online) London: BMJ Group, Pharmaceutical Press, and RCPCH Publications. Accessed 5, June 2022. http:\/\/www.medicinescomplete.com."},{"key":"10.1016\/j.survophthal.2023.01.002_bib0148","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O\u2019Shea","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0149","doi-asserted-by":"crossref","unstructured":"O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 72:111-115.","DOI":"10.1136\/annrheumdis-2012-202576"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0150","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.42037","article-title":"American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis","volume":"74","author":"Onel","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0151","first-page":"2501","article-title":"Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis","volume":"31","author":"Ortiz-Alvarez","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0152","unstructured":"Oxford Centre for Evidence-Based Medicine: Levels of evidence (March 2009) \u2014 centre for evidence-based medicine (CEBM) U of O, Https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009. No Title."},{"key":"10.1016\/j.survophthal.2023.01.002_bib0153","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2009.05.008","article-title":"Azathioprine for ocular inflammatory diseases","author":"Pasadhika","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0154","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/092739490500282","article-title":"Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies","volume":"12","author":"Perez","year":"2004","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0155","first-page":"3300","article-title":"Relationship between injection site reactions and different adalimumab formulations. Analysis of the adverse events reported in Italy in the period 2016-2019","volume":"25","author":"Pilunni","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0156","unstructured":"Positioning statements on physician-led switching for biosimilar medicines. https:\/\/www.medicinesforeurope.com\/docs\/M-Biosimilars-Overview-of-positions-on-physician-led-switching.pdf%0D."},{"key":"10.1016\/j.survophthal.2023.01.002_bib0157","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","article-title":"ADJUVITE: A double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis","volume":"77","author":"Quartier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0158","doi-asserted-by":"crossref","unstructured":"Quesada-Masachs E, Caballero CM. Subcutaneous tocilizumab may be less effective than intravenous tocilizumab in the treatment of juvenile idiopathic arthritis\u2013associated uveitis. J Rheumatol 44:260-261. doi:10.3899\/jrheum.160908.","DOI":"10.3899\/jrheum.160908"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0159","doi-asserted-by":"crossref","unstructured":"Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology;113. doi:10.1016\/j.ophtha.2005.09.037.","DOI":"10.1016\/j.ophtha.2005.09.037"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0160","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S2665-9913(20)30008-4","article-title":"Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial","volume":"2","author":"Ramanan","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0161","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-018-0010-2","article-title":"A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)","volume":"2","author":"Ramanan","year":"2018","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0162","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0163","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-021-05651-5","volume":"22","author":"Ramanan","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0164","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1745-6215-15-14","article-title":"A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)","volume":"15","author":"Ramanan","year":"2014","journal-title":"Trials"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0165","first-page":"12598376","article-title":"Use of methotrexate in juvenile idiopathic arthritis","author":"Ramanan","year":"2003","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0166","doi-asserted-by":"crossref","unstructured":"Reimold AM. New indications for treatment of chronic inflammation by TNF-alpha blockade. Am J Med. 2003; Sci 325:75\u201392.","DOI":"10.1097\/00000441-200302000-00005"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0167","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-019-0366-x","article-title":"Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis","volume":"17","author":"Renton","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0168","doi-asserted-by":"crossref","DOI":"10.1111\/j.1442-9071.2005.01062.x","article-title":"Infliximab for juvenile idiopathic arthritis-associated uveitis","author":"Richards","year":"2005","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0169","doi-asserted-by":"crossref","DOI":"10.1097\/RHU.0000000000001707","article-title":"Weekly adalimumab, an effective alternative for refractory uveitis in children","author":"Roberts","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0170","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40674-018-0092-4","article-title":"Addressing Mental Health in Pediatric Rheumatology","volume":"4","author":"Rubinstein","year":"2018","journal-title":"Curr Treat Options in Rheum"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0171","first-page":"1","article-title":"A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis","volume":"11","author":"Rusche","year":"2021","journal-title":"Sci Reports"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0172","doi-asserted-by":"crossref","unstructured":"S. WR, J. D, C. B, C.L. D, G. VV, N. A. A search for variables predicting cortisol response to low-dose corticotropin stimulation following supraphysiological doses of glucocorticoids. J Pediatr. 2013; 163:484\u2013488 1. doi:10.1016\/j.jpeds.2013.01.011.","DOI":"10.1016\/j.jpeds.2013.01.011"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0173","first-page":"72","article-title":"2016 update of the Portuguese recommendations for the use of biological therapies in children and adolescents with Juvenile Idiopathic Arthritis","volume":"2018","author":"Santos","year":"2018","journal-title":"Acta Reumatol Por"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0174","doi-asserted-by":"crossref","unstructured":"Sardar E, Dusser P, Rousseau A, Bodaghi B, Labetoulle M, Kon\u00e9-Paut I Retrospective study evaluating treatment decisions and outcomes of childhood uveitis not associated with juvenile idiopathic arthritis. J Pediatr 186:131\u2013137. doi:10.1016\/j.jpeds.2017.03.052.","DOI":"10.1016\/j.jpeds.2017.03.052"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0175","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kel030","article-title":"Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis","volume":"45","author":"Saurenmann","year":"2006","journal-title":"Rheumatol (Oxford"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0176","doi-asserted-by":"crossref","unstructured":"Schatz CS, Uzel JL, Leininger L, Danner S, Terzic J, Fischbach M. Immunosuppressants used in a steroid-sparing strategy for childhood uveitis. J Pediatr Ophthalmol Strabismus 44:28\u201334.","DOI":"10.3928\/01913913-20070101-03"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0177","doi-asserted-by":"crossref","unstructured":"Schiff MH, Burmester GR, Kent JD. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65:889\u2013894.","DOI":"10.1136\/ard.2005.043166"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0178","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/rheumatology\/keh658","article-title":"Etanercept and uveitis in patients with juvenile idiopathic arthritis","volume":"44","author":"Schmeling","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0179","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12969-017-0189-6","article-title":"Cross sectional, qualitative thematic analysis of patient perspectives of disease impact in juvenile idiopathic arthritis-associated uveitis","volume":"15","author":"Sen","year":"2017","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0180","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.berh.2018.01.002","article-title":"Juvenile idiopathic arthritis-associated uveitis","volume":"31","author":"Sen","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0181","first-page":"9","article-title":"Current therapeutic approaches to autoimmune chronic uveitis in children","author":"Simonini","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0182","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/acr.22214","article-title":"Current evidence of anti-tumor necrosis factor\u00a0?? treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs","volume":"66","author":"Simonini","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0183","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/rheumatology\/kes186","article-title":"Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach","volume":"52","author":"Simonini","year":"2013","journal-title":"Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0184","first-page":"47","article-title":"Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis","author":"Simonini","year":"2008","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0185","doi-asserted-by":"crossref","unstructured":"Smith J a., Thompson DJS, Whitcup SM, et\u00a0al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Care Res 2005;53:18-23. doi:10.1002\/art.20904.","DOI":"10.1002\/art.20904"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0186","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/09273948.2021.1900276","article-title":"Efficacy of biosimilar adalimumab in the treatment of Beh\u00e7et\u2019s uveitis","volume":"30","author":"Soheilian","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0187","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/bjophthalmol-2018-313789","article-title":"Areas of agreement in the management of childhood non-infectious chronic anterior uveitis in the UK","volume":"104","author":"Solebo","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0188","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/APO.0000000000000380","article-title":"Effectiveness of SB5, an adalimumab biosimilar, in patients with noninfectious uveitis: a real-life monocentric experience","volume":"10","author":"Sota","year":"2021","journal-title":"Asia-Pacific J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0189","first-page":"151","article-title":"Tocilizumab in refractory juvenile idiopathic arthritis with associated uveitis: a case report","volume":"44","author":"Sousa-Neves","year":"2019","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0190","doi-asserted-by":"crossref","unstructured":"ST AH, MS L, LA H, et\u00a0al. Childhood arthritis and rheumatology research alliance consensus treatment plans for juvenile idiopathic arthritis-associated and idiopathic chronic anterior uveitis. Arthritis Care Res 71(PG-482-491):482-491. doi:10.1002\/acr.23610.","DOI":"10.1002\/acr.23610"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0191","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/bjo.82.6.704","article-title":"Systemic corticosteroid therapy: side effects and their management","volume":"82","author":"Stanbury","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0192","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/rheumatology\/key280","article-title":"The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases?","volume":"58","author":"Tanaka","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0193","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.3899\/jrheum.160231","article-title":"evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis","volume":"43","author":"Tappeiner","year":"2016","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.survophthal.2023.01.002_bib0195","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/eye.2008.174","article-title":"Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis","volume":"23","author":"Tappeiner","year":"2009","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0196","first-page":"1271","article-title":"The frequency and clinical course of COVID-19 infection in children with juvenile idiopathic arthritis","volume":"38","author":"Yildiz","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0197","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/09273948.2013.866254","article-title":"Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient","volume":"22","author":"Tsang","year":"2014","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0198","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","article-title":"Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et's disease: an open-label trial","volume":"52","author":"Tugal-Tutkun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0199","first-page":"1","article-title":"Real-life data on efficacy and safety of original adalimumab and biosimilar adalimumab (ABP 501) in pediatric rheumatic diseases","author":"Ulu","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0200","article-title":"Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis","volume":"17","author":"Utz","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0201","doi-asserted-by":"crossref","unstructured":"V MU, S B, S L, et\u00a0al. Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis. Pediatr Rheumatol Online J. 2019; 29;17:7 doi:10.1186\/s12969-019-0383-9.","DOI":"10.1186\/s12969-019-0383-9"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0202","doi-asserted-by":"crossref","unstructured":"Viswanathan V, KJ M. Management of children with juvenile idiopathic arthritis. Indian J Pediatr. 2016; 83(PG-63-70):63-70. doi:10.1007\/s12098-015-1966-1.","DOI":"10.1007\/s12098-015-1966-1"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0203","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/anr.1780320604","article-title":"Toxicirty and serum levels of methotrexate in children with juvenile rheumatoid arthritis","volume":"32","author":"Wallace","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0204","doi-asserted-by":"crossref","unstructured":"Wang SL, Hauenstein S, Ohrmund L, et\u00a0al. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. J Pharm Biomed Anal 79:39\u201344. doi:10.1016\/j.jpba.2013.01.031.","DOI":"10.1016\/j.jpba.2013.01.031"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0205","first-page":"175","article-title":"British Association of Dermatologists\u2019 guidelines for the safe and effective prescribing of methotrexate for skin disease 2016","author":"Warren","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0206","doi-asserted-by":"crossref","unstructured":"Wennink RAW, Ayuso VK, Vries LA, Vastert SJ, Boer JH. Tocilizumab as an effective treatment option in children with refractory intermediate and panuveitis. Ocul Immunol Inflamm. 2021; 2;29:21. doi:10.1080\/09273948.2020.1712431.","DOI":"10.1080\/09273948.2020.1712431"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0207","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1080\/09273948.2018.1529800","article-title":"Efficacy of high-dose methotrexate in pediatric non-infectious uveitis","volume":"27","author":"Wieringa","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0208","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jmii.2013.03.005","article-title":"Risk of tuberculosis infection in anti-TNF-\u03b1 biological therapy: from bench to bedside","volume":"47","author":"Xie","year":"2014","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0209","first-page":"71","article-title":"Primary (month-6) outcomes of the STOP-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis","volume":"(v;183:","author":"YJ","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0210","doi-asserted-by":"crossref","first-page":"23118110","DOI":"10.3899\/jrheum.120583","article-title":"Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year follow-up data from the Italian Registry","volume":"40","author":"Zannin","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0211","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.2147\/DDDT.S317382","article-title":"An Update review of biosimilars of adalimumab in psoriasis - bioequivalence and interchangeability","volume":"15","author":"Zhou","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.survophthal.2023.01.002_bib0212","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/acr.20115","article-title":"Abatacept for severe anti\u2013tumor necrosis factor \u03b1 refractory juvenile idiopathic arthritis\u2013related uveitis","volume":"62","author":"Zulian","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625723000012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625723000012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:57:10Z","timestamp":1758542230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625723000012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":211,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0039625723000012"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2023.01.002","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on the systemic management of noninfectious uveitis in children and adolescents","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2023.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}